IL98163A - Isoxazole-4-carboxamides and hydroxyalkylidenzano azamides, and new compounds of this type - Google Patents

Isoxazole-4-carboxamides and hydroxyalkylidenzano azamides, and new compounds of this type

Info

Publication number
IL98163A
IL98163A IL9816391A IL9816391A IL98163A IL 98163 A IL98163 A IL 98163A IL 9816391 A IL9816391 A IL 9816391A IL 9816391 A IL9816391 A IL 9816391A IL 98163 A IL98163 A IL 98163A
Authority
IL
Israel
Prior art keywords
carbon atoms
alkyl
mono
halogen
bromine
Prior art date
Application number
IL9816391A
Other languages
English (en)
Hebrew (he)
Other versions
IL98163A0 (en
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of IL98163A0 publication Critical patent/IL98163A0/xx
Publication of IL98163A publication Critical patent/IL98163A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/23—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/40—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
IL9816391A 1990-05-18 1991-05-16 Isoxazole-4-carboxamides and hydroxyalkylidenzano azamides, and new compounds of this type IL98163A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4016178 1990-05-18
DE4017020 1990-05-26
DE4017043 1990-05-26

Publications (2)

Publication Number Publication Date
IL98163A0 IL98163A0 (en) 1992-06-21
IL98163A true IL98163A (en) 1996-01-31

Family

ID=27201216

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9816391A IL98163A (en) 1990-05-18 1991-05-16 Isoxazole-4-carboxamides and hydroxyalkylidenzano azamides, and new compounds of this type

Country Status (28)

Country Link
US (2) US5494911A (fr)
EP (1) EP0527736B1 (fr)
JP (3) JP2995086B2 (fr)
KR (1) KR100188801B1 (fr)
CN (1) CN1051074C (fr)
AT (1) ATE151633T1 (fr)
AU (2) AU649421B2 (fr)
BR (1) BR9008022A (fr)
CA (1) CA2083179C (fr)
CY (1) CY2123B1 (fr)
CZ (4) CZ290474B6 (fr)
DE (1) DE59010701D1 (fr)
DK (1) DK0527736T3 (fr)
ES (1) ES2102367T3 (fr)
FI (1) FI105683B (fr)
GR (1) GR3023638T3 (fr)
HU (1) HU222234B1 (fr)
IE (1) IE911694A1 (fr)
IL (1) IL98163A (fr)
LV (1) LV10575B (fr)
NO (1) NO180118C (fr)
NZ (1) NZ238165A (fr)
PT (1) PT97689B (fr)
RU (2) RU2084223C1 (fr)
SK (3) SK281317B6 (fr)
TW (2) TW205004B (fr)
WO (1) WO1991017748A1 (fr)
YU (1) YU48765B (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235563A (en) * 1989-10-13 1993-04-28 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical composition
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
GB9300083D0 (en) * 1993-01-05 1993-03-03 Roussel Lab Ltd Chemical compounds
DE59407414D1 (de) * 1993-01-08 1999-01-21 Hoechst Ag Verwendung von Leflunomid zur Hemmung von Tumornekrosefaktor alpha
ES2125356T3 (es) * 1993-01-08 1999-03-01 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 8.
EP0607775B1 (fr) * 1993-01-08 1998-12-09 Hoechst Aktiengesellschaft Utilisation de leflunomid pour inhiber interleukin 1 bêta
EP0607774B1 (fr) * 1993-01-08 1998-12-09 Hoechst Aktiengesellschaft Utilisation de leflunomid pour inhiber l'interleukin 1 alpha
TW314467B (fr) * 1993-03-31 1997-09-01 Hoechst Ag
GB9313365D0 (en) * 1993-06-29 1993-08-11 Roussel Lab Ltd Chemical compounds
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
GB9322781D0 (en) * 1993-11-04 1993-12-22 Roussel Lab Ltd Aromatic amides
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US5721277A (en) * 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
GB9520092D0 (en) * 1995-10-02 1995-12-06 Hoechst Roussel Ltd Chemical compounds
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DK0795334T3 (da) * 1996-03-12 2006-06-06 Sanofi Aventis Deutschland Nye prodrugs til behandling af tumorer og betændelsessygdomme
DE19610955A1 (de) * 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
BR9712005A (pt) * 1996-09-04 1999-08-24 Pfizer Derivados de indazol e seus usos como inibidores de fosfodiesterase (pde) tipo IV e produ-Æo do fator de necrose de tumor (tnf)
DE19702988A1 (de) * 1997-01-28 1998-07-30 Hoechst Ag Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika
US6316479B1 (en) * 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
EP1012150A4 (fr) * 1997-05-19 2002-05-29 Sugen Inc Composes d'heteroarylcarboxamide actifs contre les etats pathologiques lies aux proteine tyrosine kinases
DE59801792D1 (de) * 1997-08-08 2001-11-22 Aventis Pharma Gmbh Kristallform von N-(4-Trifluormethylphenyl)-5-methylisoxazol-4-carbonsäureamid
WO1999023076A1 (fr) * 1997-11-04 1999-05-14 Pfizer Products Inc. Composes therapeutiquement actifs obtenus par remplacement du catechol par un bio-isostere d'indazole dans des inhibiteurs de pde4
JP2002512216A (ja) * 1998-04-17 2002-04-23 パーカー ヒューズ インスティテュート Ｂｔｋインヒビターならびにその同定方法および使用方法
US6303652B1 (en) * 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
HUP0204069A3 (en) * 1999-12-16 2005-01-28 Teva Pharma Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
EP1257270B1 (fr) * 2000-02-15 2005-04-13 Teva Pharmaceutical Industries Ltd. Procede permettant d'effectuer la synthese du leflunomide
US20030055263A1 (en) * 2001-07-11 2003-03-20 Boehringer Ingelheim Pharma Kg Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production
DE10133665A1 (de) * 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
US6858637B2 (en) 2002-03-28 2005-02-22 Neurogen Corporation Substituted biaryl amides as C5a receptor modulators
AU2003225971A1 (en) * 2002-03-28 2003-10-13 Yang Gao Substituted biaryl amides as c5a receptor modulators
JP2006505571A (ja) * 2002-10-15 2006-02-16 リゲル ファーマシューテイカルズ、インコーポレイテッド 置換されたインドール及びｈｃｖ阻害剤としてのその使用
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
PT1768966E (pt) 2004-06-17 2012-05-23 Infinity Discovery Inc Compostos e métodos para inibir a interacção de proteínas bcl com parceiros de ligação
CA2571710A1 (fr) 2004-06-24 2006-11-02 Nicholas Valiante Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
DE102006014165A1 (de) * 2006-03-24 2007-09-27 Schebo Biotech Ag Neue Isooxazol-Derivate und deren Verwendungen
CA2659155A1 (fr) * 2006-07-20 2008-01-24 Amgen Inc. Heterocycles aromatiques d'azole substitues, utilises en tant qu'inhibiteurs de ll~-hsd-1
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
ES2398606T3 (es) * 2007-05-03 2013-03-20 Pfizer Limited Derivados de 2-piridin-carboxamida como moduladores de los canales de sodio
US20090076275A1 (en) * 2007-09-19 2009-03-19 David Robert Bolin Diacylglycerol acyltransferase inhibitors
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010075549A2 (fr) 2008-12-23 2010-07-01 Pharmasset, Inc. Phosphoramidates de nucléosides
CN102325783A (zh) 2008-12-23 2012-01-18 法莫赛特股份有限公司 嘌呤核苷的合成
US8551973B2 (en) * 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
US9006454B2 (en) 2009-04-02 2015-04-14 Merck Serono S.A. Dihydroorotate dehydrogenase inhibitors
EP2236505A1 (fr) * 2009-04-03 2010-10-06 Bayer CropScience AG Aminopyridines et pyridazines acylés en tant qu'insecticides
EP2451773A2 (fr) 2009-07-09 2012-05-16 Alembic Pharmaceuticals Limited Nouvelle forme polymorphe de sels de teriflunomide
SI3290428T1 (sl) 2010-03-31 2022-01-31 Gilead Pharmasset Llc Tableta, ki obsega kristalinični (S)-izopropil 2-(((S)-(((2R,3R,4R,5R) -5-(2,4-diokso-3,4-dihidropirimidin-1(2H)-il)-4-fluoro-3-hidroksi-4- metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino)propanoat
US8957098B2 (en) 2010-08-24 2015-02-17 Algiax Pharmaceuticals Gmbh Use of leflunomide and malononitrilamides
NO2632451T3 (fr) 2010-10-29 2018-03-17
WO2012110911A1 (fr) 2011-02-18 2012-08-23 Alembic Pharmaceuticals Limited Nouvelle forme polymorphe de tériflunomide
WO2012123353A1 (fr) 2011-03-17 2012-09-20 Algiax Pharmaceuticals Gmbh Nouvelle utilisation de benzofuranylsulfonates
EP2685983B1 (fr) 2011-03-17 2016-05-18 Algiax Pharmaceuticals GmbH Nouvelle utilisation d'imidazotriazinones
EP3019482B1 (fr) 2013-02-25 2018-08-15 Aurigene Discovery Technologies Limited Dérivés de benzotriazole trisubstitués à titre d'inhibiteurs de dihydroorotate oxygénase
WO2015029063A2 (fr) * 2013-08-30 2015-03-05 Msn Laboratories Private Limited Nouveau polymorphe de (4-trifluorométhyl-phényl)-amide d'acide (z)-2-cyano-3-hydroxy-but-2-énoïque et son procédé de préparation
US20160287549A1 (en) 2013-11-22 2016-10-06 Genzyme Corporation Novel methods for treating neurodegenerative diseases
AU2015205374B2 (en) 2014-01-13 2018-08-23 Aurigene Oncology Limited Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
CU20160188A7 (es) * 2014-06-20 2017-06-05 Aurigene Discovery Tech Ltd Compuestos de indazole substituidos como inhibidores de irak4
CN105272882B (zh) * 2014-07-23 2019-05-31 欣凯医药化工中间体（上海）有限公司 一种环保简便制备泰瑞米特的方法
RU2722316C2 (ru) * 2015-06-17 2020-05-29 Биокон Лимитед Новый способ получения терифлуномида
EP3585772B1 (fr) 2017-02-24 2023-10-11 Merck Patent GmbH Dérivés de 2-alkyl-1h-benzo[d]imidazole, 1, 4,6-trisubstitués comme inhibiteurs de dihydro-orotate-oxygénase
BR112019018991A2 (pt) 2017-03-31 2020-04-14 Aurigene Discovery Technologies Limited compostos e composições para tratar distúrbios hematológicos
LT3615027T (lt) 2017-04-24 2021-10-25 Aurigene Discovery Technologies Limited Tripakeistųjų benzotriazolo darinių kaip dihidroorotato oksigenazės inhibitorių naudojimo būdai
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
EA202090497A1 (ru) 2017-10-31 2020-11-23 Кьюрис, Инк. Соединения и композиции для лечения гематологических нарушений
TR202022336A2 (tr) 2020-12-30 2022-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet comprising teriflunomide
EP4162933A1 (fr) 2021-10-08 2023-04-12 Algiax Pharmaceuticals GmbH Composé pour le traitement de la stéatose hépatique non alcoolique et des maladies associées

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES448386A1 (es) * 1975-06-05 1978-04-16 Hoechst Ag Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico.
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE2524959C2 (de) * 1975-06-05 1983-02-10 Hoechst Ag, 6000 Frankfurt 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
DE2557003A1 (de) * 1975-12-18 1977-06-23 Hoechst Ag Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
DE2555789A1 (de) * 1975-12-11 1977-07-07 Hoechst Ag Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
DE2655009A1 (de) * 1976-12-04 1978-06-15 Hoechst Ag Isoxazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
DE3405727A1 (de) * 1984-02-17 1985-08-22 Hoechst Ag, 6230 Frankfurt Isoxazol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
GB8619432D0 (en) * 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
GB8619433D0 (en) * 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
US4816467A (en) * 1987-01-09 1989-03-28 Farmitalia Carlo Erba S.R.L Heteroaryl 3-oxo-propanenitrile derivatives, pharmaceutical compositions and use

Also Published As

Publication number Publication date
JPH11343285A (ja) 1999-12-14
CY2123B1 (en) 2002-06-21
NO180118C (no) 1997-02-19
JPH05506425A (ja) 1993-09-22
AU6546890A (en) 1991-12-10
EP0527736A1 (fr) 1993-02-24
NZ238165A (en) 1994-08-26
CA2083179C (fr) 2001-10-23
RU94033835A (ru) 1996-04-20
KR100188801B1 (ko) 1999-06-01
TW211558B (fr) 1993-08-21
NO180118B (no) 1996-11-11
PT97689A (pt) 1992-02-28
CZ290717B6 (cs) 2002-10-16
NO924433L (no) 1992-11-17
DE59010701D1 (de) 1997-05-22
SK281316B6 (sk) 2001-02-12
HUT64314A (en) 1993-12-28
SK281318B6 (sk) 2001-02-12
ATE151633T1 (de) 1997-05-15
FI105683B (fi) 2000-09-29
CA2083179A1 (fr) 1991-11-19
CZ290474B6 (cs) 2002-07-17
EP0527736B1 (fr) 1997-04-16
IL98163A0 (en) 1992-06-21
JP3201747B2 (ja) 2001-08-27
US5532259A (en) 1996-07-02
FI925211A0 (fi) 1992-11-17
JP2995086B2 (ja) 1999-12-27
RU2142937C1 (ru) 1999-12-20
LV10575A (lv) 1995-04-20
IE911694A1 (en) 1991-11-20
NO924433D0 (no) 1992-11-17
AU649421B2 (en) 1994-05-26
YU48765B (en) 1999-11-22
GR3023638T3 (en) 1997-08-29
DK0527736T3 (da) 1997-10-20
SK281317B6 (sk) 2001-02-12
AU662465B2 (en) 1995-08-31
CN1056684A (zh) 1991-12-04
PT97689B (pt) 1998-09-30
BR9008022A (pt) 1993-04-06
CN1051074C (zh) 2000-04-05
CS145091A3 (en) 1992-01-15
CZ290736B6 (cs) 2002-10-16
US5494911A (en) 1996-02-27
HU222234B1 (hu) 2003-05-28
AU5799294A (en) 1994-07-07
CZ290737B6 (cs) 2002-10-16
LV10575B (en) 1996-04-20
HU9203619D0 (en) 1993-03-29
WO1991017748A1 (fr) 1991-11-28
RU2084223C1 (ru) 1997-07-20
JP3233610B2 (ja) 2001-11-26
JPH11322700A (ja) 1999-11-24
YU88491A (sh) 1995-03-27
FI925211A (fi) 1992-11-17
TW205004B (fr) 1993-05-01
ES2102367T3 (es) 1997-08-01

Similar Documents

Publication Publication Date Title
IL98163A (en) Isoxazole-4-carboxamides and hydroxyalkylidenzano azamides, and new compounds of this type
JP4437270B2 (ja) 置換複素環式尿素を用いたｒａｆキナーゼの阻害
EP1670787B1 (fr) Inhibiteurs des cytokines
KR100719166B1 (ko) ｒａｆ 키나아제 저해제로서의 ω-카르복시아릴 치환 디페닐 우레아
JP2008513508A (ja) 炎症及び免疫に関連する用途に用いる化合物
WO2002062763A2 (fr) Inhibition de raf kinase a l'aide de quinolyl, isoquinolyl ou pyridyl urees
PT1651232E (pt) Compostos para inflamação e utilizações imunorelacionadas
CN111153846B (zh) 吡咯类化合物、其制备方法和药物组合物与用途
EP1103543A1 (fr) Nouveaux derives d'uree renfermant des heterocycles aromatiques azotes
US4542139A (en) Sulfonylureas pharmaceutical formulations based on these compounds and their use for treatment of diabetes
FI105680B (fi) Menetelmä terapeuttisesti käyttökelpoisten hydroksialkylideenisyaanietikkahappoamidien valmistamiseksi
LT3416B (en) Isoxazole-4-carboxamides, hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and method for the preparation of such drugs
US4402964A (en) N-Aryl-N'-(3-methyl or ethyl-4-oxothiazolidinylidene)ureas useful for the treatment of epilepsy
UA135630U (uk) 2-((5-((2,5-диметоксифеніл)аміно)-1,3,4-тіадіазол-2-іл)тіо)-n-(нафтилен-1-іл)ацетамід, що проявляє діуретичну активність
Sontakke et al. CONVENIENT ROUTE FOR STUDYING REACTIVITY OF ISOTHIOCYANATES TOWARDS BARBITURYL ISOTHIOCARBAMIDE

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
HP Change in proprietorship
KB Patent renewed
EXP Patent expired